Poretz D M, Woolard D, Eron L J, Goldenberg R I, Rising J, Sparks S
Am J Med. 1984 Oct 19;77(4C):77-83.
Patients who participated in an outpatient intravenous therapy program designed to limit hospitalization for those who could be maintained on ceftriaxone at home were interviewed regarding costs and benefits. Of the 79 patients interviewed concerning 83 therapeutic episodes, 43.4 percent were able to perform their usual activities as soon as they began the program, 28.9 percent were restricted for part of the time, and 27.7 percent never resumed their usual activities. The 83 therapeutic episodes represent a total of 2,409 outpatient days (mean 29.7; standard deviation [SD] 17.7), 1,406 of which represent unrestricted activities. Costs and benefits of the program were calculated separately for four employment groups: not employed; usually employed, but not while on intravenous therapy; employed while on intravenous therapy, with time off for follow-up visits; and employed while on intravenous therapy, no time off for follow-up required. The mean total benefit, weighted across all four groups, was $6,588.14 (SD = $3,802.90) per patient. Mean weighted costs totalled $1,768.02 (SD = $1,129.36). The overall weighted benefit/cost ratio was approximately 5:1. Although private insurers reimbursed 63 percent of the patients for all hospitalization costs, only 39 percent were fully covered for the follow-up physician visits required during outpatient therapy.
参与门诊静脉治疗项目的患者接受了关于成本和效益的访谈。该项目旨在减少那些在家中接受头孢曲松治疗即可维持病情的患者的住院次数。在接受访谈的79名患者中，共涉及83个治疗疗程。其中，43.4%的患者在开始治疗后能够立即恢复日常活动，28.9%的患者在部分时间内受到限制，27.7%的患者从未恢复日常活动。这83个治疗疗程共计2409个门诊日（平均29.7天；标准差[SD]17.7天），其中1406个门诊日代表不受限制的活动。该项目的成本和效益针对四个就业群体分别进行了计算：未就业；通常就业，但在接受静脉治疗期间不工作；在接受静脉治疗期间工作，但需请假进行随访；在接受静脉治疗期间工作，无需请假进行随访。所有四个群体的加权平均总效益为每位患者6588.14美元（标准差 = 3802.90美元）。加权平均成本总计1768.02美元（标准差 = 1129.36美元）。总体加权效益/成本比约为5:1。尽管私人保险公司为63%的患者报销了所有住院费用，但只有39%的患者在门诊治疗期间所需的随访医生就诊费用得到了全额覆盖。
